Annual CFI
-$2.47 B
+$717.00 M+22.51%
December 31, 2024
Summary
- As of February 23, 2025, REGN annual cash flow from investing activities is -$2.47 billion, with the most recent change of +$717.00 million (+22.51%) on December 31, 2024.
- During the last 3 years, REGN annual CFI has risen by +$2.92 billion (+54.16%).
- REGN annual CFI is now -2021.13% below its all-time high of $128.47 million, reached on December 31, 2011.
Performance
REGN Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
$350.60 M
+$925.00 M+161.04%
December 31, 2024
Summary
- As of February 23, 2025, REGN quarterly cash flow from investing activities is $350.60 million, with the most recent change of +$925.00 million (+161.04%) on December 31, 2024.
- Over the past year, REGN quarterly CFI has stayed the same.
- REGN quarterly CFI is now -75.88% below its all-time high of $1.45 billion, reached on June 30, 2020.
Performance
REGN Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
-$2.47 B
+$416.80 M+14.45%
December 31, 2024
Summary
- As of February 23, 2025, REGN TTM cash flow from investing activities is -$2.47 billion, with the most recent change of +$416.80 million (+14.45%) on December 31, 2024.
- Over the past year, REGN TTM CFI has stayed the same.
- REGN TTM CFI is now -515.16% below its all-time high of $594.50 million, reached on June 30, 2020.
Performance
REGN TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
REGN Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +22.5% | 0.0% | 0.0% |
| 3 y3 years | +54.2% | 0.0% | 0.0% |
| 5 y5 years | -21.7% | 0.0% | 0.0% |
REGN Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +54.2% | at high | +114.7% | -6.6% | +62.4% |
| 5 y | 5-year | -3395.9% | +54.2% | -75.9% | +114.4% | -515.2% | +62.4% |
| alltime | all time | -2021.1% | +54.2% | -75.9% | +114.4% | -515.2% | +62.4% |
Regeneron Pharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$2.47 B(-22.5%) | $350.60 M(-161.0%) | -$2.47 B(-14.4%) |
| Sep 2024 | - | -$574.40 M(+3.1%) | -$2.88 B(+2.8%) |
| Jun 2024 | - | -$557.20 M(-67.0%) | -$2.81 B(-39.5%) |
| Mar 2024 | - | -$1.69 B(+2448.5%) | -$4.64 B(+45.6%) |
| Dec 2023 | -$3.19 B(-15.8%) | -$66.20 M(-86.7%) | -$3.19 B(-36.0%) |
| Sep 2023 | - | -$496.30 M(-79.2%) | -$4.98 B(+16.1%) |
| Jun 2023 | - | -$2.39 B(+912.7%) | -$4.29 B(+85.2%) |
| Mar 2023 | - | -$235.70 M(-87.3%) | -$2.31 B(-38.8%) |
| Dec 2022 | -$3.78 B(-29.7%) | -$1.86 B(-1066.0%) | -$3.78 B(-3.9%) |
| Sep 2022 | - | $192.30 M(-146.5%) | -$3.94 B(-40.0%) |
| Jun 2022 | - | -$413.90 M(-75.7%) | -$6.57 B(+8.9%) |
| Mar 2022 | - | -$1.71 B(-15.3%) | -$6.03 B(+12.0%) |
| Dec 2021 | -$5.38 B(+7527.1%) | -$2.01 B(-17.5%) | -$5.38 B(+46.4%) |
| Sep 2021 | - | -$2.44 B(-2038.6%) | -$3.68 B(+82.6%) |
| Jun 2021 | - | $125.80 M(-111.9%) | -$2.01 B(+193.4%) |
| Mar 2021 | - | -$1.06 B(+247.2%) | -$686.40 M(+872.2%) |
| Dec 2020 | -$70.60 M(-96.5%) | -$305.00 M(-60.7%) | -$70.60 M(-374.7%) |
| Sep 2020 | - | -$775.80 M(-153.4%) | $25.70 M(-95.7%) |
| Jun 2020 | - | $1.45 B(-427.9%) | $594.50 M(-135.1%) |
| Mar 2020 | - | -$443.20 M(+112.4%) | -$1.69 B(-16.4%) |
| Dec 2019 | -$2.03 B(+38.6%) | -$208.70 M(+0.8%) | -$2.03 B(-2.7%) |
| Sep 2019 | - | -$207.00 M(-75.2%) | -$2.08 B(-3.7%) |
| Jun 2019 | - | -$836.00 M(+7.7%) | -$2.16 B(+19.4%) |
| Mar 2019 | - | -$776.10 M(+191.9%) | -$1.81 B(+24.0%) |
| Dec 2018 | -$1.46 B(+45.5%) | -$265.90 M(-7.3%) | -$1.46 B(-4.6%) |
| Sep 2018 | - | -$286.70 M(-40.9%) | -$1.53 B(-4.5%) |
| Jun 2018 | - | -$485.00 M(+14.0%) | -$1.61 B(+24.4%) |
| Mar 2018 | - | -$425.40 M(+26.7%) | -$1.29 B(+28.4%) |
| Dec 2017 | -$1.01 B(-4.0%) | -$335.76 M(-6.4%) | -$1.01 B(+6.9%) |
| Sep 2017 | - | -$358.88 M(+110.6%) | -$940.69 M(-4.8%) |
| Jun 2017 | - | -$170.41 M(+21.6%) | -$987.66 M(-13.6%) |
| Mar 2017 | - | -$140.14 M(-48.3%) | -$1.14 B(+9.2%) |
| Dec 2016 | -$1.05 B(+15.3%) | -$271.25 M(-33.2%) | -$1.05 B(+16.5%) |
| Sep 2016 | - | -$405.85 M(+24.5%) | -$898.85 M(+15.8%) |
| Jun 2016 | - | -$326.01 M(+646.3%) | -$776.17 M(-5.6%) |
| Mar 2016 | - | -$43.69 M(-64.6%) | -$821.80 M(-9.5%) |
| Dec 2015 | -$907.60 M(+115.7%) | -$123.30 M(-56.5%) | -$907.60 M(+24.7%) |
| Sep 2015 | - | -$283.17 M(-23.8%) | -$727.66 M(+28.2%) |
| Jun 2015 | - | -$371.65 M(+187.0%) | -$567.55 M(+80.7%) |
| Mar 2015 | - | -$129.48 M(-328.6%) | -$314.03 M(-25.4%) |
| Dec 2014 | -$420.78 M(+18.4%) | $56.65 M(-146.0%) | -$420.78 M(-28.4%) |
| Sep 2014 | - | -$123.07 M(+4.2%) | -$587.37 M(-13.5%) |
| Jun 2014 | - | -$118.12 M(-50.0%) | -$678.75 M(+52.9%) |
| Mar 2014 | - | -$236.23 M(+114.9%) | -$444.00 M(+24.9%) |
| Dec 2013 | -$355.45 M(+338.4%) | -$109.95 M(-48.7%) | -$355.45 M(+130.2%) |
| Sep 2013 | - | -$214.45 M(-283.9%) | -$154.40 M(-1467.1%) |
| Jun 2013 | - | $116.63 M(-179.0%) | $11.29 M(-104.6%) |
| Mar 2013 | - | -$147.69 M(-262.1%) | -$244.52 M(+201.6%) |
| Dec 2012 | -$81.07 M(-163.1%) | $91.10 M(-286.9%) | -$81.07 M(-60.7%) |
| Sep 2012 | - | -$48.75 M(-65.0%) | -$206.08 M(+30.2%) |
| Jun 2012 | - | -$139.19 M(-982.8%) | -$158.23 M(-227.7%) |
| Mar 2012 | - | $15.77 M(-146.5%) | $123.89 M(-3.6%) |
| Dec 2011 | $128.47 M(-129.4%) | -$33.91 M(+3655.0%) | $128.47 M(-166.8%) |
| Sep 2011 | - | -$903.00 K(-100.6%) | -$192.24 M(+36.2%) |
| Jun 2011 | - | $142.94 M(+602.5%) | -$141.17 M(-49.6%) |
| Mar 2011 | - | $20.35 M(-105.7%) | -$280.28 M(-35.9%) |
| Dec 2010 | -$437.03 M(<-9900.0%) | -$354.62 M(-806.8%) | -$437.03 M(+330.2%) |
| Sep 2010 | - | $50.17 M(+1213.4%) | -$101.58 M(-38.5%) |
| Jun 2010 | - | $3.82 M(-102.8%) | -$165.22 M(+70.8%) |
| Mar 2010 | - | -$136.40 M(+611.5%) | -$96.72 M(<-9900.0%) |
| Dec 2009 | $146.00 K(-99.5%) | -$19.17 M(+42.3%) | $146.00 K(-99.9%) |
| Sep 2009 | - | -$13.47 M(-118.6%) | $103.99 M(-42.3%) |
| Jun 2009 | - | $72.33 M(-282.9%) | $180.24 M(-486.2%) |
| Mar 2009 | - | -$39.54 M(-146.7%) | -$46.67 M(-251.4%) |
| Dec 2008 | $30.82 M | $84.67 M(+34.9%) | $30.82 M(-277.2%) |
| Sep 2008 | - | $62.78 M(-140.6%) | -$17.39 M(-78.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2008 | - | -$154.58 M(-507.4%) | -$82.04 M(-411.6%) |
| Mar 2008 | - | $37.94 M(+4.1%) | $26.33 M(-130.7%) |
| Dec 2007 | -$85.72 M(-44.7%) | $36.46 M(-2045.7%) | -$85.72 M(-70.0%) |
| Sep 2007 | - | -$1.87 M(-95.9%) | -$285.40 M(+31.5%) |
| Jun 2007 | - | -$46.20 M(-37.7%) | -$217.06 M(-0.6%) |
| Mar 2007 | - | -$74.11 M(-54.6%) | -$218.35 M(+40.8%) |
| Dec 2006 | -$155.10 M(-234.3%) | -$163.21 M(-345.6%) | -$155.10 M(-564.2%) |
| Sep 2006 | - | $66.46 M(-240.0%) | $33.41 M(+162.1%) |
| Jun 2006 | - | -$47.48 M(+336.8%) | $12.75 M(-85.2%) |
| Mar 2006 | - | -$10.87 M(-143.0%) | $86.20 M(-25.4%) |
| Dec 2005 | $115.49 M(-2620.1%) | $25.30 M(-44.8%) | $115.49 M(+27.8%) |
| Sep 2005 | - | $45.80 M(+76.4%) | $90.35 M(+134.3%) |
| Jun 2005 | - | $25.97 M(+40.9%) | $38.57 M(-164.9%) |
| Mar 2005 | - | $18.43 M(>+9900.0%) | -$59.39 M(+1195.9%) |
| Dec 2004 | -$4.58 M(-92.8%) | $163.00 K(-102.7%) | -$4.58 M(-97.2%) |
| Sep 2004 | - | -$5.99 M(-91.7%) | -$161.24 M(+65.2%) |
| Jun 2004 | - | -$71.99 M(-198.3%) | -$97.62 M(+86.2%) |
| Mar 2004 | - | $73.23 M(-146.8%) | -$52.43 M(-17.9%) |
| Dec 2003 | -$63.84 M(+9.1%) | -$156.49 M(-371.6%) | -$63.84 M(-150.0%) |
| Sep 2003 | - | $57.63 M(-315.1%) | $127.58 M(+27.5%) |
| Jun 2003 | - | -$26.80 M(-143.3%) | $100.06 M(+10.9%) |
| Mar 2003 | - | $61.82 M(+77.0%) | $90.23 M(-254.2%) |
| Dec 2002 | -$58.52 M(-22.4%) | $34.94 M(+16.1%) | -$58.52 M(-51.1%) |
| Sep 2002 | - | $30.10 M(-182.2%) | -$119.66 M(-30.1%) |
| Jun 2002 | - | -$36.63 M(-57.9%) | -$171.25 M(+1.2%) |
| Mar 2002 | - | -$86.93 M(+231.7%) | -$169.20 M(+124.4%) |
| Dec 2001 | -$75.39 M(+30.7%) | -$26.21 M(+22.0%) | -$75.39 M(+18.0%) |
| Sep 2001 | - | -$21.49 M(-37.9%) | -$63.91 M(-27.5%) |
| Jun 2001 | - | -$34.58 M(-602.1%) | -$88.10 M(+65.3%) |
| Mar 2001 | - | $6.89 M(-146.7%) | -$53.30 M(-7.6%) |
| Dec 2000 | -$57.68 M(-437.3%) | -$14.73 M(-67.7%) | -$57.68 M(+14.8%) |
| Sep 2000 | - | -$45.68 M(<-9900.0%) | -$50.24 M(-905.8%) |
| Jun 2000 | - | $226.00 K(-91.0%) | $6.24 M(-36.4%) |
| Mar 2000 | - | $2.51 M(-134.4%) | $9.81 M(-42.6%) |
| Dec 1999 | $17.10 M(+584.0%) | -$7.30 M(-167.6%) | $17.10 M(-38.0%) |
| Sep 1999 | - | $10.80 M(+184.2%) | $27.60 M(+112.3%) |
| Jun 1999 | - | $3.80 M(-61.2%) | $13.00 M(-24.9%) |
| Mar 1999 | - | $9.80 M(+206.3%) | $17.30 M(+592.0%) |
| Dec 1998 | $2.50 M(-106.4%) | $3.20 M(-184.2%) | $2.50 M(-117.7%) |
| Sep 1998 | - | -$3.80 M(-146.9%) | -$14.10 M(-26.2%) |
| Jun 1998 | - | $8.10 M(-262.0%) | -$19.10 M(-54.2%) |
| Mar 1998 | - | -$5.00 M(-62.7%) | -$41.70 M(+7.2%) |
| Dec 1997 | -$38.90 M(-12.2%) | -$13.40 M(+52.3%) | -$38.90 M(+2.6%) |
| Sep 1997 | - | -$8.80 M(-39.3%) | -$37.90 M(+16.3%) |
| Jun 1997 | - | -$14.50 M(+559.1%) | -$32.60 M(-0.6%) |
| Mar 1997 | - | -$2.20 M(-82.3%) | -$32.80 M(-26.0%) |
| Dec 1996 | -$44.30 M(-698.6%) | -$12.40 M(+254.3%) | -$44.30 M(+53.3%) |
| Sep 1996 | - | -$3.50 M(-76.2%) | -$28.90 M(+18.4%) |
| Jun 1996 | - | -$14.70 M(+7.3%) | -$24.40 M(+916.7%) |
| Mar 1996 | - | -$13.70 M(-556.7%) | -$2.40 M(-132.4%) |
| Dec 1995 | $7.40 M(-76.8%) | $3.00 M(+200.0%) | $7.40 M(-67.5%) |
| Sep 1995 | - | $1.00 M(-86.3%) | $22.80 M(-10.6%) |
| Jun 1995 | - | $7.30 M(-287.2%) | $25.50 M(+8.1%) |
| Mar 1995 | - | -$3.90 M(-121.2%) | $23.60 M(-26.0%) |
| Dec 1994 | $31.90 M(-235.2%) | $18.40 M(+397.3%) | $31.90 M(-878.0%) |
| Sep 1994 | - | $3.70 M(-31.5%) | -$4.10 M(-80.4%) |
| Jun 1994 | - | $5.40 M(+22.7%) | -$20.90 M(+2.0%) |
| Mar 1994 | - | $4.40 M(-125.0%) | -$20.50 M(-13.1%) |
| Dec 1993 | -$23.60 M(-387.8%) | -$17.60 M(+34.4%) | -$23.60 M(+807.7%) |
| Sep 1993 | - | -$13.10 M(-325.9%) | -$2.60 M(-122.2%) |
| Jun 1993 | - | $5.80 M(+346.2%) | $11.70 M(+56.0%) |
| Mar 1993 | - | $1.30 M(-61.8%) | $7.50 M(-8.5%) |
| Dec 1992 | $8.20 M(-110.6%) | $3.40 M(+183.3%) | $8.20 M(+70.8%) |
| Sep 1992 | - | $1.20 M(-25.0%) | $4.80 M(+33.3%) |
| Jun 1992 | - | $1.60 M(-20.0%) | $3.60 M(+80.0%) |
| Mar 1992 | - | $2.00 M | $2.00 M |
| Dec 1991 | -$77.60 M | - | - |
FAQ
- What is Regeneron Pharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals annual CFI year-on-year change?
- What is Regeneron Pharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals quarterly CFI year-on-year change?
- What is Regeneron Pharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for Regeneron Pharmaceuticals?
- What is Regeneron Pharmaceuticals TTM CFI year-on-year change?
What is Regeneron Pharmaceuticals annual cash flow from investing activities?
The current annual CFI of REGN is -$2.47 B
What is the all time high annual CFI for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high annual cash flow from investing activities is $128.47 M
What is Regeneron Pharmaceuticals annual CFI year-on-year change?
Over the past year, REGN annual cash flow from investing activities has changed by +$717.00 M (+22.51%)
What is Regeneron Pharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of REGN is $350.60 M
What is the all time high quarterly CFI for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high quarterly cash flow from investing activities is $1.45 B
What is Regeneron Pharmaceuticals quarterly CFI year-on-year change?
Over the past year, REGN quarterly cash flow from investing activities has changed by $0.00 (0.00%)
What is Regeneron Pharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of REGN is -$2.47 B
What is the all time high TTM CFI for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals all-time high TTM cash flow from investing activities is $594.50 M
What is Regeneron Pharmaceuticals TTM CFI year-on-year change?
Over the past year, REGN TTM cash flow from investing activities has changed by $0.00 (0.00%)